Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

1. Histologically confirmed HER2-positive (defined as IHC3+ or IHC2+ with ISH positivity) locally advanced or metastatic GEA
2. Documented plan to initiate a zanidatamab-containing therapy as 1L treatment
3. Sufficient cognitive capacity and language proficiency to complete patient-reported outcomes (PRO) questions
4. 18 years of age or older on the date of initiating 1L zanidatamab-containing therapy

1. Receiving a zanidatamab-containing therapy as part of a clinical trial or expanded access program
2. Received zanidatamab prior to the approval date by the FDA for HER2+ la/m GEA
3. Received the first infusion of zanidatamab prior to providing study consent
4. For patients initiating chemotherapy backbone first, more than 2 months have elapsed before the first dose of zanidatamab

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA